clinical trial · NCT04950127
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
GlaxoSmithKline·phase3·completed·n = 238
PruritusLinerixibatPlacebo
brief summary
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
started
Aug 27, 2021
primary completion
Oct 28, 2024
completion
Dec 20, 2024
last updated
Jul 22, 2025
official title
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol